Cost-effectiveness of toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China and the United States healthcare systems

Key Points

• This analysis aims to assess the cost-effectiveness of toripalimab plus bevacizumab versus sorafenib in treating advanced hepatocellular carcinoma.
• Cost-effectiveness analysis comparing toripalimab plus bevacizumab and sorafenib
• Evaluation based on current pricing levels
• Assessment conducted within China and U.S. healthcare systems
• Toripalimab plus bevacizumab is unlikely to be cost-effective compared to sorafenib
• Findings apply to both China and the U.S. healthcare systems
• Highlights the importance of value-based pricing strategies